Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: Comparison with tamoxifen and raloxifene

Journal of Psychiatry and Neuroscience

Volumn 30, Issue 2, 2005, Pages 110-117

  Le Saux, Maryvonne ^a   Di Paolo, Thérèse ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTIDEPRESSANT AGENT; ESTRADIOL; ESTROGEN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); NEUROLEPTIC AGENT; POSTSYNAPTIC RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; TAMOXIFEN CITRATE; ANTIESTROGEN; SEROTONIN AGONIST; TAMOXIFEN;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; DENDRITE; DENTATE GYRUS; ESTROGEN THERAPY; FEMALE; HIPPOCAMPUS; MOOD DISORDER; NONHUMAN; OVARIECTOMY; PROTEIN PROTEIN INTERACTION; RAPHE NUCLEUS; RAT; RECEPTOR UPREGULATION; SEROTONINERGIC TRANSMISSION; UTERUS WEIGHT; ANIMAL; BRAIN LEVEL; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; ORGAN SIZE; SPRAGUE DAWLEY RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; AUTORADIOGRAPHY; BRAIN CHEMISTRY; ESTROGEN ANTAGONISTS; FEMALE; GTP-BINDING PROTEINS; ORGAN SIZE; OVARIECTOMY; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; TAMOXIFEN;

EID: 17544381918     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999;20(3):279-307.
2. McEwen BS. Clinical review 108: the molecular and neuroanatomical basis for estrogen effects in the central nervous system. J Clin Endocrinol Metab 1999;84(6):1790-7.
3. Cyr M, Calon F, Morissette M, Grandbois M, Di Paolo T, Callier S. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr Pharm Des 2000;6(12):1287-312.
4. Buckwalter JG, Stanczyk FZ, McCleary CA, Bluestein BW, Buckwalter DK, Rankin KP, et al. Pregnancy, the postpartum, and steroid hormones: effects on cognition and mood. Psychoneuroendocrinology 1999;24(1):69-84.
5. Panay N, Studd JW. The psychotherapeutic effects of estrogens. Gynecol Endocrinol 1998;12(5):353-65.
6. Zapantis G, Santoro N. The menopausal transition: characteristics and management. Best Pract Res Clin Endocrinol Metab 2003;17(1):33-52.
7. Bosse R, Di Paolo T. The modulation of brain dopamine and GABAA receptors by estradiol: a clue for CNS changes occurring at menopause. Cell Mol Neurobiol 1996;16(2):199-212.
8. Benes FM. Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 2000;31(2-3):251-69.
9. Blier P, Lista A, De Montigny C. Differential properties of pre- and postsynaptic 5-hydroxytryptamine1A receptors in the dorsal raphe and hippocampus: II. Effect of pertussis and cholera toxins. J Pharmacol Exp Ther 1993;265(1):16-23.
10. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38(8):1083-152.
11. Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci 1998;18(18):7394-401.
12. Lu NZ, Bethea CL. Ovarian steroid regulation of 5-HT1A receptor binding and G protein activation in female monkeys. Neuropsychopharmacology 2002;27(1):12-24.
13. Osterlund MK, Kurd YL. Acute 17 beta-estradiol treatment downregulates serotonin 5HT1A receptor mRNA expression in the limbic system of female rats. Brain Res Mol Brain Res 1998;55(1):169-72.
14. Osterlund MK, Halldin C, Kurd YL. Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A) receptor rnRNA and binding levels in the rat brain. Synapse 2000;35(1):39-44.
15. Jackson A, Etgen AM. Estrogen modulates 5-HT(1A) agonist inhibition of lordosis behavior but not binding of [(3)H]-8-OH-DPAT. Pharmacol Biochem Behav 2001;68(2):221-7.
16. Sovago J, Dupuis DS, Gulyas B, Hall H. An overview on functional receptor autoradiography using [35S]GTPgammaS. Brain Res Brain Res Rev 2001;38(1-2):149-64.
17. Mize AL, Alper RH. Acute and long-term effects of 17beta-estradiol on G(i/o) coupled neurotransmitter receptor function in the female rat brain as assessed by agonist-stimulated [35S]GTPgammaS binding. Brain Res 2000;859(2):326-33.
18. Mize AL, Alper RH. Rapid uncoupling of serotonin-1A receptors in rat hippocampus by 17beta-estradiol in vitro requires protein kinases A and C. Neuroendocrinology 2002;76(6):339-47.
19. Mize AL, Young LJ, Alper RH. Uncoupling of 5-HT1A receptors in the brain by estrogens: regional variations in antagonism by ICI 182,780. Neuropharmacology 2003;44(5):584-91.
20. Giguere V, Yang N, Segui P, Evans RM. Identification of a new class of steroid hormone receptors. Nature 1988;331(6151):91-4.
21. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93(12):5925-30.
22. Sanchez R, Nguyen D, Rocha W, White JH, Mader S. Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 2002;24(3):244-54.
23. Belcher SM, Zsarnovszky A. Estrogenic actions in the brain: estrogen, phytoestrogens, and rapid intracellular signaling mechanisms. J Pharmacol Exp Ther 2001;299(2):408-14.
24. Laflamme N, Nappi RE, Drolet G, Labrie C, Rivest S. Expression and neuropeptidergic characterization of estrogen receptors (ERa1pha and ERbeta) throughout the rat brain: anatomical evidence of distinct roles of each subtype. J Neurobiol 1998;36(3):357-78.
25. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol 1997;388(4):507-25.
26. Sismondi P, Biglia N, Giai M, Ponzone R, Roagna R, Sgro L, et al. HRT, breast and endometrial cancers: strategies and intervention options. Maturitas 1999;32(3):131-9.
27. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10(8):905-12.
28. Grese TA, Dodge JA. Selective estrogen receptor modulators (SERMs). Curr Pharm Des 1998;4(1):71-92.
29. Dhandapani KM, Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 2002;67(5):1379-85.
30. Jones CD, Jevnikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR, et al. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2- arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl) benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 1984;27(8):1057-66.
31. Cyr M, Landry M, Di Paolo T. Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 2000;23(1):69-78.
32. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic Press; 1998.
33. Bonhomme N, Cador M, Stinus L, Le Moal M, Spampinato U. Short and long-term changes in dopamine and serotonin receptor binding sites in amphetamine-sensitized rats: a quantitative autoradiographic study. Brain Res 1995;675(1-2):215-23.
34. Waeber C, Moskowitz MA. 5-Hydroxytryptamine1A and 5-hydroxytryptarnine1B receptors stimulate [35S]guanosrne-5′-O-(3-thio)triphosphate binding to rodent brain sections as visualized by in vitro autoradiography. Mol Pharmacol 1997;52(4):623-31.
35. Meller E, Li H, Carr KD, Hiller JM. 5-Hydroxytryptamine(1A) receptor-stimulated [(35)S]GTPgammaS binding in rat brain: absence of regional differences in coupling efficiency. J Pharmacol Exp Ther 2000;292(2):684-91.
36. Sim-Selley LJ, Vogt LJ, Xiao R, Childers SR, Selley DE. Region-specific changes in 5-HT(1A) receptor-activated G-proteins in rat brain following chronic buspirone. Eur J Pharmacol 2000;389(2-3):147-53.
37. Li Q, Muma NA, van de Kar LD. Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(O) proteins and in neuroendocrine responses to a 5-HT1A agonist. J Pharmacol Exp Ther 1996;279(2):1035-42.
38. Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002;23(1):41-100.
39. Bethea CL, Mirkes SJ, Su A, Michelson D. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques. Psychoneuroendocrinology 2002;27(4):431-45.
40. Landry M, Di Paolo T. Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor. Brain Res Mol Brain Res 2003;112(1-2):82-9.
41. Mann JJ. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999;21(2 Suppl):99S-105S.
42. Butler JA, Kallo I, Sjoberg M, Coen CW. Evidence for extensive distribution of oestrogen receptor alpha-immunoreactivity in the cerebral cortex of adult rats. J Neuroendocrinol 1999;11(5):325-9.
43. Shughrue PJ, Lane MV, Merchenthaler I. Biologically active estrogen receptor-beta: evidence from in vivo autoradiographic studies with estrogen receptor alpha-knockout mice. Endocrinology 1999;140(6):2613-20.
44. Parks CL, Shenk T. The serotonin 1a receptor gene contains a TATA-less promoter that responds to MAZ and Sp1. J Biol Chem 1996;271(8):4417-30.
45. Porter W, Saville B, Hoivik D, Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 1997;11(11):1569-80.
46. Shughrue PJ, Merchenthaler I. Evidence for novel estrogen binding sites in the rat hippocampus. Neuroscience 2000;99(4):605-12.
47. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001;62:231-52.
48. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, et al. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 2000;275(8):5379-87.
49. Clarke WP, Goldfarb J. Estrogen enhances a 5-HT1A response in hippocampal slices from female rats. Eur J Pharmacol 1989;160(1):195-7.
50. Clarke WP, Maayani S. Estrogen effects on 5-HT1A receptors in hippocampal membranes from ovariectomized rats: functional and binding studies. Brain Res 1990;518(1-2):287-91.
51. Beck SG, Clarke WP, Goldfarb J. Chronic estrogen effects on 5-hydroxytryptamine-mediated responses in hippocampal pyramidal cells of female rats. Neurosci Lett 1989;106(1-2):181-7.
52. Rudick CN, Woolley CS. Selective estrogen receptor modulators regulate phasic activation of hippocampal CA1 pyramidal cells by estrogen. Endocrinology 2003;144(1):179-87.
53. Elena Castro M, Diaz A, del Olmo E, Pazos A. Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT1A receptors in rat brain. Neuropharmacology 2003;44(1):93-101.
54. Hensler JG. Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 2002;26(5):565-73.
55. Shen C, Li H, Meller E. Repeated treatment with antidepressants differentially alters 5-HT(1A) agonist-stimulated [(35)S]GTPgammaS binding in rat brain regions. Neuropharmacology 2002;42(8): 1031-8.
56. Cyr M, Ghribi O, Thibault C, Morissette M, Landry M, Di Paolo T. Ovarian steroids and selective estrogen receptor modulators activity on rat brain NMDA and AMPA receptors. Brain Res Brain Res Rev 2001;37(1-3):153-61.
57. Cyr M, Ghribi O, Di Paolo T. Regional and selective effects of oestradiol and progesterone on NMDA and AMPA receptors in the rat brain. J Neuroendocrinol 2000;12(5):445-52.
58. Cyr M, Thibault C, Morissette M, Landry M, Di Paolo T. Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain. Neuropsychopharmacology 2001;25(2):242-57.